EA200800786A1 - Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем - Google Patents

Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем

Info

Publication number
EA200800786A1
EA200800786A1 EA200800786A EA200800786A EA200800786A1 EA 200800786 A1 EA200800786 A1 EA 200800786A1 EA 200800786 A EA200800786 A EA 200800786A EA 200800786 A EA200800786 A EA 200800786A EA 200800786 A1 EA200800786 A1 EA 200800786A1
Authority
EA
Eurasian Patent Office
Prior art keywords
igf
derivatives
tetragidrobenzoazepinovye
deactivation
standardization
Prior art date
Application number
EA200800786A
Other languages
English (en)
Inventor
Ян Гунцингер
Курт Леандер
Original Assignee
Аналитикон С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аналитикон С.А. filed Critical Аналитикон С.А.
Publication of EA200800786A1 publication Critical patent/EA200800786A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems

Abstract

Синтезированы соединения формулы (I). Обнаружено, что они регулируют понижающим образом или ингибируют экспрессию или функцию рецептора IGF-1.
EA200800786A 2005-09-09 2006-09-08 Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем EA200800786A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71517005P 2005-09-09 2005-09-09
IB2005002667 2005-09-09
PCT/IB2006/002474 WO2007029107A1 (en) 2005-09-09 2006-09-08 Isoquinolines derivatives as igf-1r inhibitors

Publications (1)

Publication Number Publication Date
EA200800786A1 true EA200800786A1 (ru) 2008-08-29

Family

ID=37460368

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800786A EA200800786A1 (ru) 2005-09-09 2006-09-08 Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем

Country Status (10)

Country Link
US (1) US20090099133A1 (ru)
EP (1) EP1940796A1 (ru)
JP (1) JP2009507820A (ru)
KR (1) KR20080065591A (ru)
AU (1) AU2006288847A1 (ru)
BR (1) BRPI0616731A2 (ru)
CA (1) CA2621820A1 (ru)
EA (1) EA200800786A1 (ru)
NO (1) NO20081206L (ru)
WO (1) WO2007029107A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
US20140045847A1 (en) * 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
AU2015220750B2 (en) * 2014-02-24 2020-04-16 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
TR201911032T4 (tr) * 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
BRPI0418462A (pt) * 2004-03-12 2007-06-05 Analytecon Sa derivados de tetrahidroisoquinolina e terahidrobenzazepina como inibidores igf-1r

Also Published As

Publication number Publication date
JP2009507820A (ja) 2009-02-26
BRPI0616731A2 (pt) 2016-08-23
CA2621820A1 (en) 2007-03-15
AU2006288847A1 (en) 2007-03-15
US20090099133A1 (en) 2009-04-16
KR20080065591A (ko) 2008-07-14
WO2007029107A1 (en) 2007-03-15
EP1940796A1 (en) 2008-07-09
NO20081206L (no) 2008-05-29

Similar Documents

Publication Publication Date Title
EA200800786A1 (ru) Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем
UY29479A1 (es) Inhibidores de adn-pk
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
ATE479687T1 (de) Kinaseinhibitoren
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
NO20061321L (no) Kinazolinderivater som tyrosin kinase inhibitorer
ATE512151T1 (de) Pyrrolotriazin-kinaseinhibitoren
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
WO2007008704A3 (en) Melanocortin receptor ligands
MY146989A (en) Kinase inhibitors
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
ATE508119T1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
RS53599B1 (en) PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS
DK2270008T3 (da) 8-Heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-oner som PI-3-kinaseinhibitorer
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0518607A2 (pt) derivados de pirrol tendo atividade antagonista de receptor crth2
WO2007120333A3 (en) Tetracyclic kinase inhibitors
AR058127A1 (es) Derivados de piperidina antagonistas de cgrp, procedimientos para su preparacion asi como su uso como medicamentos
DK1711177T3 (da) 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer
UA85505C2 (en) Kinase inhibitors